A multidisciplinary care team is needed when treating patients who are given a combination of chemotherapy and immunotherapy.
When treating patients with chemotherapy plus an immunotherapy agent, a multidisciplinary team should be on call to manage adverse events (AEs), explained Matthew A. Gubens, MD, MS, associate professor of thoracic medical oncology at the UCSF Helen Diller Family Comprehensive Cancer Center.
The combination is usually well-tolerated, with typical chemotherapy AEs occurring, such as nausea and vomiting. When it comes to immunotherapy, the same AEs that would be expected if the drug was given as a single agent could be expected, Gubens said.
Nurses Exchange Best Strategies in Improving Delivery of Hepatic Artery Infusion Pump Education
May 1st 2023Kathleen Gander DNP, APRN, CNS; and Sarah Middlekauff, MSN, RN, OCN, relay their experiences in implementing a hepatic artery infusion pump educational intervention for oncology nurses.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
2 Clarke Drive
Cranbury, NJ 08512